NDA 022418 · Rosemont
Fibricor
Fenofibric Acid · Oral
DiscontinuedLast checked: Nov 20, 2026Latest source record: Jun 6, 2025 (newest FDA action)Source: Drugs@FDA, openFDA, CMS, ClinicalTrials.gov, PubMedMethods & limitations
First approved
2009
Aug 14, 2009
Approved uses
1
Original approval plus efficacy supplements
Registered trials
33
11 Phase 3, 2 recruiting
FAERS reports
0
0 serious, 0 with death reported
AI brief across all sources
Written by AI from the FDA, CMS, ClinicalTrials.gov, FAERS and PubMed data on this page, plus web searches for pricing, exclusivity and pending FDA decisions.
What it is approved for
No structured label for this application in openFDA. Older and discontinued products often have none.
Approval history
Original approval and efficacy supplements (new uses, populations or doses), newest first, with FDA's letters and labels.
- Aug 14, 2009 Original approval · Type 5 - New Formulation or New Manufacturer ReviewSummary ReviewLetter
2 products under this application
- FIBRICOR · FENOFIBRIC ACID 105MG · TABLET, ORAL · Discontinued
- FIBRICOR · FENOFIBRIC ACID 35MG · TABLET, ORAL · Discontinued
Clinical trials
Interventional ClinicalTrials.gov studies with "Fenofibric Acid" as an intervention, any sponsor and status, largest first.
- Study to Evaluate the Long-Term Safety and Efficacy of ABT-335, in Combination With Three Different Statins in Subjects With Mixed Dyslipidemia.Pivotal-lookingCompleted
AbbottIndustry
NCT00300430 · 1,911 participants · Start Sep 2006 · Primary completion Mar 2008
Drug: ABT-335 and rosuvastatin calcium; ABT-335 and atorvastatin calcium and 1 more · For: Dyslipidemia; Coronary Heart Disease; Mixed Dyslipidemia
Sites: North Chicago, Illinois
- Evaluate Safety and Efficacy of ABT-335 in Combination With Rosuvastatin Calcium in Subjects With Multiple Abnormal Lipid Levels in the BloodPivotal-lookingCompleted
AbbottIndustry
NCT00300482 · 1,445 participants · Start Mar 2006 · Primary completion Dec 2006
Drug: ABT-335; Rosuvastatin Calcium and 1 more · For: Dyslipidemia; Coronary Heart Disease; Mixed Dyslipidemia
Sites: North Chicago, Illinois
- A Multicenter Study Comparing the Safety and Efficacy of ABT-335 and Rosuvastatin Calcium Combination Therapy to Monotherapy in Subjects With DyslipidemiaPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00463606 · 760 participants · Start Apr 2007 · Primary completion Feb 2008
Drug: ABT-335 and rosuvastatin calcium; ABT-335 and 1 more · For: Hypercholesterolemia; Dyslipidemia
Sites: Birmingham, Alabama; Huntsville, Alabama; Ozark, Alabama · 168 sites in all
- Safety and Efficacy Study Using ABT-335 (Investigational Drug) in Combination With Atorvastatin, to Study the Effects on Thickening of the Blood Vessel Wall in Patients With Abnormal Lipid (Fat) Levels in the BloodPivotal-lookingCompleted
AbbVie (prior sponsor, Abbott)AbbVie (ABBV)
NCT00616772 · 682 participants · Start Feb 2008 · Primary completion Sep 2012
Drug: ABT-335; Placebo · For: Coronary Artery Disease; Coronary Heart Disease; Dyslipidemia
Sites: Chandler, Arizona; Gilbert, Arizona; Mesa, Arizona · 124 sites in all
- Evaluate Safety and Efficacy of ABT-335 in Combination With Atorvastatin in Subjects With Multiple Abnormal Lipid Levels in the BloodPivotal-lookingCompleted
AbbottIndustry
NCT00300469 · 613 participants · Start Mar 2006 · Primary completion Feb 2007
Drug: ABT-335; Atorvastatin and 1 more · For: Mixed Dyslipidemia; Coronary Heart Disease; Dyslipidemia
Sites: North Chicago, Illinois
- Safety and Efficacy Study Comparing ABT-335 Coadministered With Atorvastatin and Ezetimibe to Atorvastatin Coadministered With Ezetimibe in Subjects With Multiple Abnormal Lipid (Fat) Levels in the BloodPivotal-lookingCompleted
AbbottIndustry
NCT00639158 · 543 participants · Start Feb 2008 · Primary completion Oct 2008
Drug: ABT-335; placebo and 2 more · For: Dyslipidemias; Coronary Heart Disease; Combined (Atherogenic) Dyslipidemia and 1 more
Sites: Birmingham, Alabama; Columbiana, Alabama; Hueytown, Alabama · 118 sites in all
- Safety and Efficacy Study Comparing ABT-143 to Simvastatin in Subjects With Elevated Levels of Low Density Lipoprotein Cholesterol ("Bad Cholesterol") and TriglyceridesPivotal-lookingCompleted
AstraZenecaAstraZeneca (AZN)
NCT00812955 · 474 participants · Start Nov 2008 · Primary completion Jun 2009
Drug: ABT-143; simvastatin · For: Dyslipidemia, Hypercholesterolemia, Hypertriglyceridemia
Sites: Birmingham, Alabama; Columbiana, Alabama; Huntsville, Alabama · 129 sites in all
- A Year 2, Safety Extension Study of the Combination of ABT-335 and Statin Therapy for Subjects With Mixed DyslipidemiaPivotal-lookingCompleted
AbbottIndustry
NCT00491530 · 310 participants · Start Jun 2007 · Primary completion Nov 2008
Drug: ABT-335; rosuvastatin calcium and 2 more · For: Mixed Dyslipidemia
Sites: Abbott Park, Illinois
Most reported adverse reactions
FAERS reports naming this application or brand. Unverified reports, not rates; a report can name several drugs.
No FAERS reports name this application.
FAERS reports by year
By the date FDA received the report.
No reports.
Recalls
0 FDA enforcement reports for this application.
No recalls on record for this application.
Shortages
FDA's drug shortage list.
Not on FDA's shortage list.
Medicare spending
CMS Spending by Drug. Part D is pharmacy-dispensed; Part B is given in a clinic or hospital outpatient setting. Spending is before manufacturer rebates.
Not found under this brand name in Medicare's Part D or Part B Spending by Drug data. CMS lists some drugs under the generic name only.
Published evidence
PubMed clinical trials, meta-analyses and systematic reviews, most relevant first.
- Adverse events of statin-fenofibric acid versus statin monotherapy: a meta-analysis of randomized controlled trials.
Geng Q, Ren J, Chen H, et al. · Curr Med Res Opin 2013 · Meta-Analysis, Research Support, Non-U.S. Gov't
- Systematic literature review and meta-analysis of dual therapy with fenofibrate or fenofibric acid and a statin versus a double or equivalent dose of statin monotherapy.
Ouwens MJ, Nauta J, Ansquer JC, et al. · Curr Med Res Opin 2015 · Comparative Study, Meta-Analysis
- Effect of gemfibrozil and fenofibrate on the pharmacokinetics of atorvastatin.
Whitfield LR, Porcari AR, Alvey C, et al. · J Clin Pharmacol 2011 · Clinical Trial, Comparative Study
- Pharmacokinetics and comparative bioavailability of two fenofibrate capsule formulations in healthy volunteers.
Vlase L, Popa A, Muntean D, et al. · Arzneimittelforschung 2010 · Comparative Study, Randomized Controlled Trial
- Ordered mesoporous silica to enhance the bioavailability of poorly water-soluble drugs: Proof of concept in man.
Bukara K, Schueller L, Rosier J, et al. · Eur J Pharm Biopharm 2016 · Randomized Controlled Trial
- Effects of niacin, statin, and fenofibrate on circulating proprotein convertase subtilisin/kexin type 9 levels in patients with dyslipidemia.
Khera AV, Qamar A, Reilly MP, et al. · Am J Cardiol 2015 · Multicenter Study, Randomized Controlled Trial
Sponsor: Rosemont
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.